Trials / Completed
CompletedNCT01510860
Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis
Double-blind, Double-dummy, Randomised, Crossover, Multicentre Phase IV Clinical Study Comparing the Effect of Ursofalk 500 mg Tablets od Versus Ursofalk 250 mg Capsules od on Liver Enzymes in the Treatment of Primary Biliary Cirrhosis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Dr. Falk Pharma GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy of Ursofalk 500 mg tablets versus Ursofalk 500 mg capsules in the treatment of Primary Biliary Cirrhosis (PBC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | UDCA (Ursodeoxycholic acid) | 250 mg |
| DRUG | UDCA (Ursodeoxycholic acid) | 500 mg |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2010-07-01
- Completion
- 2010-07-01
- First posted
- 2012-01-18
- Last updated
- 2019-05-07
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01510860. Inclusion in this directory is not an endorsement.